Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).

Basit Öğe Kaydı
dc.contributor.authorChan, Arlene
dc.contributor.authorDelaloge, Suzette
dc.contributor.authorHolmes, Frankie Ann
dc.contributor.authorMoy, Beverly
dc.contributor.authorIwata, Hiroji
dc.contributor.authorHarvey, Vernon J.
dc.contributor.authorRobert, Nicholas J.
dc.contributor.authorSilovski, Tajana
dc.contributor.authorGokmen, Erhan
dc.contributor.authorVon Minckwitz, Gunter
dc.contributor.authorEjlertsen, Bent
dc.contributor.authorChia, Stephen K. L.
dc.contributor.authorMansi, Janine
dc.contributor.authorBarrios, Carlos H.
dc.contributor.authorGnant, Michael
dc.contributor.authorWong, Alvin
dc.contributor.authorBryce, Richard
dc.contributor.authorYao, Bin
dc.contributor.authorMartin, Miguel
dc.date.accessioned2019-10-27T23:00:24Z
dc.date.available2019-10-27T23:00:24Z
dc.date.issued2015
dc.departmentEge Üniversitesien_US
dc.descriptionAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer -- MAY 29-JUN 02, 2015 -- Chicago, ILen_US
dc.description.sponsorshipAmer Soc Clin Oncolen_US
dc.identifier.doi10.1200/jco.2015.33.15_suppl.508
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue15en_US
dc.identifier.urihttps://doi.org/10.1200/jco.2015.33.15_suppl.508
dc.identifier.urihttps://hdl.handle.net/11454/51993
dc.identifier.volume33en_US
dc.identifier.wosWOS:000358036901115en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAmer Soc Clinical Oncologyen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleNeratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).en_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu